{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:10:10Z","timestamp":1790975410508,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stealth BioTherapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) is a 10-item patient-reported outcome (PRO) measure designed to assess the severity of mitochondrial disease symptoms. Analyses of data from a clinical trial with PMM patients were conducted to evaluate the psychometric properties of the PMMSA and to provide score interpretation guidelines for the measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The PMMSA was completed as a daily diary for approximately 14\u00a0weeks by individuals in a Phase 2 randomized, placebo-controlled crossover trial evaluating the safety, tolerability, and efficacy of subcutaneous injections of elamipretide in patents with mitochondrial disease. In addition to the PMMSA, performance-based assessments, clinician ratings, and other PRO measures were also completed. Descriptive statistics, psychometric analyses, and score interpretation guidelines were evaluated for the PMMSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants (N\u2009=\u200930) had a mean age of 45.3\u00a0years, with the majority of the sample being female (n\u2009=\u200925, 83.3%) and non-Hispanic white (n\u2009=\u200929, 96.6%). The 10 PMMSA items assessing a diverse symptomology were not found to form a single underlying construct. However, four items assessing tiredness and muscle weakness were grouped into a \u201cgeneral fatigue\u201d domain score. The PMMSA Fatigue 4 summary score (4FS) demonstrated stable test\u2013retest scores, internal consistency, correlations with the scores produced by reference measures, and the ability to differentiate between different global health levels. Changes on the PMMSA 4FS were also related to change scores produced by the reference measures. PMMSA severity scores were higher for the symptom rated as \u201cmost bothersome\u201d by each subject relative to the remaining nine PMMSA items (most bothersome symptom mean\u2009=\u20092.88 vs. 2.18 for other items). Distribution- and anchor-based evaluations suggested that reduction in weekly scores between 0.79 and 2.14 (scale range: 4\u201316) may represent a meaningful change on the PMMSA 4FS and reduction in weekly scores between 0.03 and 0.61 may represent a responder for each of the remaining six non-fatigue items, scored independently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Upon evaluation of its psychometric properties, the PMMSA, specifically the 4FS domain, demonstrated strong reliability and construct-related validity. The PMMSA can be used to evaluate treatment benefit in clinical trials with individuals with PMM.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      ClinicalTrials.gov identifier, NCT02805790; registered June 20, 2016;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02805790\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02805790<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-022-00534-y","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:02:59Z","timestamp":1671786179000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8130-2024","authenticated-orcid":false,"given":"Chad","family":"Gwaltney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Aiudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyar","family":"Mazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ollis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel","family":"Karaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie R.","family":"Houts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"issue":"3","key":"534_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/jmedgenet-2018-105800","volume":"56","author":"S Parikh","year":"2019","unstructured":"Parikh S, Karaa A, Goldstein A, Bertini ES, Chinnery PF, Christodoulou J et al (2019) Diagnosis of \u201cpossible\u201d mitochondrial disease: an existential crisis. J Med Genet 56(3):123\u2013130. https:\/\/doi.org\/10.1136\/jmedgenet-2018-105800","journal-title":"J Med Genet"},{"key":"534_CR2","doi-asserted-by":"publisher","first-page":"16080","DOI":"10.1038\/nrdp.2016.80","volume":"2","author":"GS Gorman","year":"2016","unstructured":"Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R et al (2016) Mitochondrial diseases. Nat Rev Dis Primers 2:16080. https:\/\/doi.org\/10.1038\/nrdp.2016.80","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"534_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1212\/WNL.0b013e31829bfe89","volume":"81","author":"S DiMauro","year":"2013","unstructured":"DiMauro S (2013) Mitochondrial encephalomyopathies\u2013fifty years on: the Robert Wartenberg Lecture. Neurology 81(3):281\u2013291. https:\/\/doi.org\/10.1212\/WNL.0b013e31829bfe89","journal-title":"Neurology"},{"issue":"26","key":"534_CR4","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1056\/NEJMra022567","volume":"348","author":"S DiMauro","year":"2003","unstructured":"DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348(26):2656\u20132668. https:\/\/doi.org\/10.1056\/NEJMra022567","journal-title":"N Engl J Med"},{"issue":"6","key":"534_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/01.bor.0000245729.17759.f2","volume":"18","author":"S DiMauro","year":"2006","unstructured":"DiMauro S (2006) Mitochondrial myopathies. Curr Opin Rheumatol 18(6):636\u2013641. https:\/\/doi.org\/10.1097\/01.bor.0000245729.17759.f2","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"534_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.nmd.2017.08.006","volume":"27","author":"M Mancuso","year":"2017","unstructured":"Mancuso M, McFarland R, Klopstock T, Hirano M (2017) International Workshop: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy. Neuromuscul Disord 27(12):1126\u20131137. https:\/\/doi.org\/10.1016\/j.nmd.2017.08.006","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"534_CR7","first-page":"35","volume":"63","author":"AM Schaefer","year":"2008","unstructured":"Schaefer AM, McFarland R, Blakely EL, He L, Whittaker RG, Taylor RW et al (2008) Prevalence of mitochondrial DNA disease in adults. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc 63(1):35\u201339","journal-title":"Ann Neurol Off J Am Neurol Assoc Child Neurol Soc"},{"key":"534_CR8","volume-title":"GeneReviews\u00ae","author":"PF Chinnery","year":"1993","unstructured":"Chinnery PF (1993) Mitochondrial disorders overview. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH et al (eds) GeneReviews\u00ae. University of Washington Seattle, Seattle, WA"},{"issue":"5","key":"534_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ana.24362","volume":"77","author":"GS Gorman","year":"2015","unstructured":"Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL et al (2015) Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 77(5):753\u2013759. https:\/\/doi.org\/10.1002\/ana.24362","journal-title":"Ann Neurol"},{"issue":"10","key":"534_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.neurol.2015.06.002","volume":"171","author":"A Behin","year":"2015","unstructured":"Behin A, Salort-Campana E, Wahbi K, Richard P, Carlier RY, Carlier P et al (2015) Myofibrillar myopathies: State of the art, present and future challenges. Rev Neurol (Paris) 171(10):715\u2013729. https:\/\/doi.org\/10.1016\/j.neurol.2015.06.002","journal-title":"Rev Neurol (Paris)"},{"issue":"5","key":"534_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197513","volume":"13","author":"Z Zolkipli-Cunningham","year":"2018","unstructured":"Zolkipli-Cunningham Z, Xiao R, Stoddart A, McCormick EM, Holberts A, Burrill N et al (2018) Mitochondrial disease patient motivations and barriers to participate in clinical trials. PLoS ONE 13(5):e0197513. https:\/\/doi.org\/10.1371\/journal.pone.0197513","journal-title":"PLoS ONE"},{"issue":"5","key":"534_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrg1606","volume":"6","author":"RW Taylor","year":"2005","unstructured":"Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6(5):389\u2013402. https:\/\/doi.org\/10.1038\/nrg1606","journal-title":"Nat Rev Genet"},{"issue":"2","key":"534_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ (2001) Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 45(2):151\u2013158","journal-title":"Arthritis Care Res"},{"issue":"3","key":"534_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000337161","volume":"38","author":"D Orsucci","year":"2012","unstructured":"Orsucci D, Calsolaro V, Siciliano G, Mancuso M (2012) Quality of life in adult patients with mitochondrial myopathy. Neuroepidemiology 38(3):194\u2013195. https:\/\/doi.org\/10.1159\/000337161","journal-title":"Neuroepidemiology"},{"key":"534_CR15","unstructured":"United Mitochondrial Disease Foundation. Voice of the Patient Report: Mitochondrial Disease: Adults with Myopathy, Children with Neurologic Symptoms. United Mitochondrial Disease Foundation; 2018. p. 1\u201378."},{"key":"534_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12320","author":"A Goldstein","year":"2020","unstructured":"Goldstein A, Rahman S (2020) Seeking impact: Global perspectives on outcome measure selection for translational and clinical research for primary mitochondrial disorders. J Inherit Metabol Dis. https:\/\/doi.org\/10.1002\/jimd.12320","journal-title":"J Inherit Metabol Dis"},{"issue":"8","key":"534_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nrneurol.2013.129","volume":"9","author":"G Pfeffer","year":"2013","unstructured":"Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S et al (2013) New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 9(8):474\u2013481. https:\/\/doi.org\/10.1038\/nrneurol.2013.129","journal-title":"Nat Rev Neurol"},{"key":"534_CR18","unstructured":"National Institutes of Health (2017). ClincalTrials.gov. Accessed 9\/19\/2017."},{"issue":"12","key":"534_CR19","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1212\/01.wnl.0000219759.72195.41","volume":"66","author":"AM Schaefer","year":"2006","unstructured":"Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM (2006) Mitochondrial disease in adults: a scale to monitor progression and treatment. Neurology 66(12):1932\u20131934. https:\/\/doi.org\/10.1212\/01.wnl.0000219759.72195.41","journal-title":"Neurology"},{"issue":"4","key":"534_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2012.12.012","volume":"23","author":"JL Elson","year":"2013","unstructured":"Elson JL, Cadogan M, Apabhai S, Whittaker RG, Phillips A, Trennell MI et al (2013) Initial development and validation of a mitochondrial disease quality of life scale. Neuromuscul Disord 23(4):324\u2013329. https:\/\/doi.org\/10.1016\/j.nmd.2012.12.012","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"534_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E et al (2011) Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: Ispor PRO good research practices task force report: part 2-assessing respondent understanding. Value Health 14(8):978\u2013988","journal-title":"Value Health"},{"issue":"8","key":"534_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E et al (2011) Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health 14(8):967\u2013977","journal-title":"Value Health"},{"key":"534_CR23","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, & Center for Devices and Radiological Health (2009). Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: Office of Communications, Division of Drug Information."},{"issue":"2","key":"534_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/cnd.0000000000000303","volume":"22","author":"C Gwaltney","year":"2020","unstructured":"Gwaltney C, Stokes J, Aiudi A, Mazar I, Ollis S, Love E et al (2020) Development of a patient-reported outcome questionnaire to evaluate primary mitochondrial myopathy symptoms: the primary mitochondrial myopathy symptom assessment. J Clin Neuromuscul Dis 22(2):65\u201376. https:\/\/doi.org\/10.1097\/cnd.0000000000000303","journal-title":"J Clin Neuromuscul Dis"},{"issue":"4","key":"534_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcsm.12559","volume":"11","author":"A Karaa","year":"2020","unstructured":"Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH (2020) A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. J Cachexia Sarcopenia Muscle 11(4):909\u2013918. https:\/\/doi.org\/10.1002\/jcsm.12559","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"14","key":"534_CR26","doi-asserted-by":"publisher","first-page":"e1212","DOI":"10.1212\/wnl.0000000000005255","volume":"90","author":"A Karaa","year":"2018","unstructured":"Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH (2018) Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 90(14):e1212\u2013e1221. https:\/\/doi.org\/10.1212\/wnl.0000000000005255","journal-title":"Neurology"},{"issue":"23","key":"534_CR27","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","volume":"78","author":"D Cella","year":"2012","unstructured":"Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D et al (2012) Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 78(23):1860\u20131867. https:\/\/doi.org\/10.1212\/WNL.0b013e318258f744","journal-title":"Neurology"},{"issue":"8","key":"534_CR28","first-page":"783","volume":"48","author":"PL Enright","year":"2003","unstructured":"Enright PL (2003) The six-minute walk test. Respir Care 48(8):783\u2013785","journal-title":"Respir Care"},{"issue":"2","key":"534_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S (1991) The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142\u2013148","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"534_CR30","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-Hubsch","year":"2006","unstructured":"Schmitz-Hubsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66(11):1717\u20131720. https:\/\/doi.org\/10.1212\/01.wnl.0000219042.60538.92","journal-title":"Neurology"},{"issue":"1","key":"534_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/1082-989x.12.1.58","volume":"12","author":"RJ Wirth","year":"2007","unstructured":"Wirth RJ, Edwards MC (2007) Item factor analysis: current approaches and future directions. Psychol Methods 12(1):58\u201379. https:\/\/doi.org\/10.1037\/1082-989x.12.1.58","journal-title":"Psychol Methods"},{"issue":"6","key":"534_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1586\/14737167.2015.1115348","volume":"15","author":"A Shields","year":"2015","unstructured":"Shields A, Coon C, Hao Y, Krohe M, Yaworsky A, Mazar I et al (2015) Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods. Expert Rev Pharmacoeconomics Outcomes Res 15(6):951\u2013959. https:\/\/doi.org\/10.1586\/14737167.2015.1115348","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"3","key":"534_CR33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11136-012-0175-x","volume":"22","author":"KW Wyrwich","year":"2013","unstructured":"Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life Research (ISOQOL) (2013) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res 22(3):475\u2013483. https:\/\/doi.org\/10.1007\/s11136-012-0175-x","journal-title":"Qual Life Res"},{"key":"534_CR34","doi-asserted-by":"publisher","DOI":"10.1201\/b16139","volume-title":"Patient-reported outcomes: measurement, implementation and interpretation","author":"JC Cappelleri","year":"2013","unstructured":"Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T (2013) Patient-reported outcomes: measurement, implementation and interpretation. CRC Press, Boca Raton, FL"},{"key":"534_CR35","volume-title":"Confirmatory factor analysis for applied research","author":"TA Brown","year":"2015","unstructured":"Brown TA (2015) Confirmatory factor analysis for applied research, 2nd edn. Guilford Publications, New York","edition":"2"},{"key":"534_CR36","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Earlbaum Associates, Hillsdale, NJ"},{"issue":"1","key":"534_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J (1992) A power primer. Psychol Bull 112(1):155\u2013159","journal-title":"Psychol Bull"},{"key":"534_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03200-4","author":"JD Peipert","year":"2022","unstructured":"Peipert JD, Hays RD, Cella D (2022) Likely change indexes improve estimates of individual change on patient-reported outcomes. Qual Life Res. https:\/\/doi.org\/10.1007\/s11136-022-03200-4. (Epub ahead of print. PMID: 35921034)","journal-title":"Qual Life Res"},{"issue":"2","key":"534_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012. (Epub 2007 Aug 3 PMID: 18177782)","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"534_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L (2017) Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health 20(7):838\u2013855. https:\/\/doi.org\/10.1016\/j.jval.2017.05.015","journal-title":"Value Health"},{"issue":"2","key":"534_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","volume":"8","author":"D Wild","year":"2005","unstructured":"Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A et al (2005) Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (pro) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 8(2):94\u2013104","journal-title":"Value Health"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-022-00534-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-022-00534-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T09:07:54Z","timestamp":1671786474000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-022-00534-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1186\/s41687-022-00534-y","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human studies described in this manuscript have been approved by the appropriate Ethics Committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participating subjects in this trial gave their informed consent prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Design, study conduct, and financial support for the study were provided by Stealth BioTherapeutics Inc. Amel Karaa is the lead Principal Investigator on the MMPOWER program and has conducted clinical trials for the Stealth BioTherapeutics\u2019 SPIMM trials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}